Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Raises A$258K

NEW YORK (GenomeWeb) – Genetic Technologies said today that its share purchase plan raised A$257,500 (US$211,000). 

The purchase plan closed on Dec. 22 and the company received applications for about 19 million shares. The new shares were issued today, Genetic Technologies said. Proceeds will be used to expand the commercialization of its BrevaGenplus breast cancer test and for general working capital. 

The Melbourne, Australia-based firm is in the midst of a restructuring effort that includes the divestiture of non-core assets in order to focus on its US molecular diagnostics business and the commercialization of the BrevaGenplus test. Last month, Genetic Technologies sold its heritage Australian Genetics business for A$2 million as part of that plan. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.